FDA approved Cimerli, the first interchangeable biosimilar to Lucentis , an eye treatment with $1.3 billion in annual sales, Cimerli-maker Coherus BioSciences announced Tuesday (Aug. 2). Cimerli also will likely compete against Eylea, another anti-VEGF treatment for wet age-related macular degeneration, though it’s not a biosimilar of that product; Eylea’s U.S. sales were more than $5 billion last year. Cimerli is expected to go on sale in October, and the company declined to say what price it plans to charge...